															CIO	פועול	<u> </u>	OF	KIVI
SUSPECT ADVERSE REACTION REPORT																			\dashv
																	_		
					1	MATION	_					_							_
PATIENT INITIALS (first, last)	first, last)							SET Yea	— '	8-12 CHECK ALL APPROPRIATE TO									
PRIVACY										" ADVERSE REACTION									
7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data) Event Verbatim [LOWER LEVEL TERM] (Related symptoms if any separated by commas)																			
painful injection [Injection site pain]								ָּר <u>ו</u>	INVOLVED OR										
the medication could not be administered [Drug dose omission by device] injection process was difficult because the pen was not friendly/it is difficult for me to use it [Device difficult to									٠, ١, ١,	PROLONGED INPATIENT HOSPITALISATION									
use]														_					
the needles of the pen were damaged [Needle issue] the pen turned with difficulty/dosing button was jammed, it did not turned/it doesn't screw it on properly									[INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR									
[Device mechanical jam]												PACITY							
80% of the medication was spilled. [Device leakage] the numbers were not visible [Device image display issue]																			
3310 11010					(Cont	inued on Ad	ditiona	al In	forma	tion	Pag	e) [LIFE THRE	ATENIN	NG	_		
II. SUSPECT DRUG(S) INFORMATION																			
14. SUSPECT DRUG(S) (include generic name) 20. DID REACTION APATE ATTER STORPING																			
#1) Genotropin Pen (SOMATROPIN) Solution for injection #2) Genotropin Pen (SOMATROPIN (DEVICE CONSTITUENT)) Solution (Continued on Additional Information Page)								e)	DRU		IEKS	IOPPI	NG						
15. DAILY DOSE(S) 16. ROUTE(S) OF ADMINISTRATION								"			_								
#1) 0.8 mg, daily #1) Unknown #2) Unknown											Ш	YES	☐ NC		NA				
17. INDICATION(S) FOR USE									21.		REAC	TION AR AFTE	=p						
#1) Unknown #2) Unknown												DUCTIO							
` '						. THERAPY DURATION							YES NO NA						
1 '					,) Unknown 2) Unknown						Ш	ILO		′ 🔼	INA			
III. CONCOMITANT DRUG(S) AND HISTORY																			
22. CONCOMITANT DRU	JG(S) AND DATES OF ADM) AND II	1010	<i>)</i> \	<u>'</u>										
23. OTHER RELEVANT I	HISTORY. (e.g. diagnostics		regnancy with last me	onth of perio	od, etc.) Description														
Unknown		,,	,		, , ,														
IV. MANUFACTURER INFORMATION																			
24a. NAME AND ADDRESS OF MANUFACTURER Pfizer S.A. 26. REMARKS																			
Laura Arce Mora Avenida Escazú, Torre Lexus, piso 7. Escazú																			
San jose, COSTA RICA																			
24b. MFR CONTROL NO.						ME AND ADDF													_
PV202500046317					NAME AND ADDRESS WITHHELD.														
24c. DATE RECEIVED BY MANUFACTURE	24d. DATE RECEIVED BY MANUFACTURER 24d. REPORT SOURCE 24d. REPORT SOURCE				NAME	NAME AND ADDRESS WITHHELD.													
30-APR-2025 STUDY LITERATURE OTHER: Spontaneous					NAME	E AND ADD	RESS	S W	ITHHI	ELD).								
DATE OF THIS REPORT	 				\dashv														
07-MAY-2025	INITIAL		FOLLOWUP:	1															

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Case Description: This is a spontaneous report received from a Consumer or other non HCP and a Nurse from product quality group, Program ID: 164974.

A 6-year-old female patient received somatropin (GENOTROPIN PEN), first regimen (Batch/Lot number: unknown) at 0.8 mg daily and second regimen (Batch/Lot number: unknown) at 0.6 mg daily, Device Lot Number: A143, Device Expiration Date: 31May2025. The patient's relevant medical history and concomitant medications were not reported.

The following information was reported: INJECTION SITE PAIN (non-serious), outcome "unknown", described as "painful injection"; DRUG DOSE OMISSION BY DEVICE (non-serious), outcome "unknown", described as "the medication could not be administered"; DEVICE DIFFICULT TO USE (non-serious), outcome "unknown", described as "injection process was difficult because the pen was not friendly/it is difficult for me to use it"; NEEDLE ISSUE (non-serious), outcome "unknown", described as "the needles of the pen were damaged"; DEVICE MECHANICAL ISSUE (non-serious), outcome "unknown", described as "the pen turned with difficulty/dosing button was jammed, it did not turned/it doesn't screw it on properly"; DEVICE LEAKAGE (non-serious), outcome "unknown", described as "80% of the medication was spilled."; DEVICE INFORMATION OUTPUT ISSUE (non-serious), outcome "unknown", described as "the numbers were not visible". The action taken for somatropin was unknown.

Causality for "painful injection", "the medication could not be administered", "injection process was difficult because the pen was not friendly/it is difficult for me to use it", "the needles of the pen were damaged", "the pen turned with difficulty/dosing button was jammed, it did not turned/it doesn't screw it on properly", "80% of the medication was spilled." and "the numbers were not visible" was determined associated to device constituent of somatropin (malfunction).

Additional information: Reporter stated the needles of the pen were damaged and the medication could not be administered because the pen turned with difficulty and the numbers were not visible, so it was not possible to set the dose. Reporter mentioned that she had two daughters and the injection process was difficult because the pen was not friendly and this led to a painful injection and she did not know if it was because of the pen or a bad administration technique. Reporter also stated that she set the medication and it did not screw correctly so 80% of the medication was spilled. Nurse stated the dosing button was jammed, it did not turned. On 16Apr2025, patient's mother reported that The pen is damaged, it is difficult for her to use it. On 30Apr2025, the reporter stated that during the consultation, the pen was checked and it was observed that the dosing knob was stuck, it did not turn.

Follow-up (16Apr2025): This is a spontaneous follow-up report received from a Consumer or other non-HCP, Program ID: 164974. Updated information included: Reaction data (event Device difficult to use subsumed, verbatim updated); clinical course

Follow-up (30Apr2025): This is a spontaneous follow-up report received from a Nurse. Updated information included: Product information (dosage, expiration date), Clinical course details added.

Batch/lot number is not provided, and it cannot be obtained.

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) Genotropin Pen (SOMATROPIN) Solution for injection; Regimen #2	0.6 mg, daily; Unknown	Unknown	Unknown; Unknown
#2) Genotropin Pen (SOMATROPIN (DEVICE CONSTITUENT)) Solution for injection {Lot # A143}; Regimen #1	; Unknown	Unknown	Unknown; Unknown